Alternating hemiplegia of childhood

Alternating hemiplegia of childhood
Synonyms	AHC
Pronounce	N/A
Specialty	N/A
Symptoms	Hemiplegia, seizures, developmental delay, movement disorders
Complications	N/A
Onset	Early infancy
Duration	Lifelong
Types	N/A
Causes	Genetic mutation in the ATP1A3 gene
Risks	Family history of genetic disorders
Diagnosis	Clinical diagnosis, genetic testing
Differential diagnosis	Epilepsy, cerebral palsy, migraine
Prevention	N/A
Treatment	Supportive care, antiepileptic drugs, physical therapy
Medication	N/A
Prognosis	Variable, often involves significant disability
Frequency	Rare, estimated 1 in 1,000,000
Deaths	N/A

A rare neurological disorder affecting children

Alternating hemiplegia of childhood (AHC) is a rare neurological disorder that typically manifests in early infancy or childhood. It is characterized by recurrent episodes of hemiplegia, which is paralysis affecting one side of the body. These episodes can alternate sides and vary in duration and frequency. AHC is a complex disorder that can also involve other neurological symptoms such as seizures, developmental delay, and movement disorders.

Signs and symptoms

The primary symptom of AHC is recurrent episodes of hemiplegia, which can last from minutes to days. These episodes can affect either side of the body and may switch sides during an episode or between episodes. In addition to hemiplegia, individuals with AHC may experience:

• Seizures
• Ataxia (lack of voluntary coordination of muscle movements)
• Dystonia (involuntary muscle contractions)
• Nystagmus (involuntary eye movements)
• Developmental delay and cognitive impairment
• Autonomic dysfunction, such as changes in heart rate and breathing

The severity and frequency of symptoms can vary widely among individuals with AHC.

Causes

AHC is primarily caused by mutations in the ATP1A3 gene, which encodes a subunit of the sodium-potassium pump (Na+/K+ ATPase). This pump is crucial for maintaining the electrochemical gradient across cell membranes, which is essential for normal neuronal function. Mutations in ATP1A3 disrupt this function, leading to the neurological symptoms observed in AHC.

Diagnosis

Diagnosing AHC can be challenging due to its rarity and the variability of symptoms. Diagnosis is typically based on clinical evaluation and the exclusion of other conditions. Genetic testing can confirm the presence of mutations in the ATP1A3 gene, supporting the diagnosis of AHC.

Treatment

There is currently no cure for AHC, and treatment focuses on managing symptoms and improving quality of life. Treatment strategies may include:

• Antiepileptic drugs to control seizures
• Physical therapy to improve motor function
• Occupational therapy to assist with daily activities
• Speech therapy for communication difficulties

Some individuals may benefit from medications such as flunarizine, which can reduce the frequency and severity of hemiplegic episodes.

Prognosis

The prognosis for individuals with AHC varies. While some may experience a reduction in the frequency and severity of episodes over time, others may have persistent and disabling symptoms. Early intervention and supportive therapies can improve outcomes and quality of life.

Related pages

• Hemiplegia
• Neurological disorder
• Seizure disorder
• Developmental delay